Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Shire’s Rare Blood Disorder Drug Gets US Fast Track

(PharmaTimes [UK]) Mar 23, 2017 - An experimental therapy in development by Shire for patients with the rare blood disorder hereditary thrombotic thrombocytopenic purpura (hTTP) has been granted a fast track designation by the US Food and Drug Administration.

read article

AML Study Correlates Gene Mutations With 34 Disease Subgroups

(OSUCCC - The James) Mar 20, 2017 - A large, new study of adults with acute myeloid leukemia (AML) correlates 80 cancer-related gene mutations with five subtypes of AML, which are defined by the presence of specific chromosomal abnormalities.

read press release

BioLineRx Reports Partial Results Data from Open-Label Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment

(StreetInsider) Mar 20, 2017 - Results to date confirm that single injection of BL-8040 mobilizes sufficient amounts of cells required for allogeneic transplantation without need for G-CSF; top-line results expected by end of 2017.

read article

New Genetic Link to Acute Lymphoblastic Leukaemia

(ICR [UK]) Mar 16, 2017 - A single letter change to DNA is linked to an increased risk of one of the most common forms of childhood leukaemia, a new study has revealed.

read article

Researchers Find Patients’ Annual Financial Burden Under Medicare Part D is “Too Much Too Soon”

(Penn Medicine) Mar 17, 2017 - A study released today by researchers at the Perelman School of Medicine at the University of Pennsylvania documents the patient out-of-pocket cost burden under Medicare prescription drug plans (known as Medicare Part D) and finds that despite having insurance, Medicare patients using specialty drugs paid thousands of dollars in out-of-pocket costs in a calendar year.

read press release

The Leukemia & Lymphoma Society Appoints Dr. Gwen Nichols as Chief Medical Officer

(LLS.org) Mar 16, 2017 - The Leukemia & Lymphoma Society (LLS), the world’s largest voluntary health agency dedicated to fighting blood cancer, announced it has appointed Gwen Nichols, M.D., chief medical officer (CMO).

read press release

Cancer Drug That Might Slow Parkinson's, Alzheimer's Headed For Bigger Tests

(NPR/Shots blog) Mar 15, 2017 - Scientists are hoping that a single drug can treat two devastating brain diseases: Parkinson's and Alzheimer's. The drug is nilotinib, which is approved to treat a form of leukemia.

read article

FDA Puts Partial Hold On Karyopharm's Cancer Drug

(BioPharma Dive) Mar 12, 2017 - Karyopharm Therapeutics said March 10 it has responded to written notice from the Food and Drug Administration that clinical trials for the pharma’s oncology drug selinexor (KPT-330) have been placed on partial clinical hold.

read article

Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed?

(Xconomy National) Mar 13, 2017 - So-called CAR-T treatments, administered experimentally in clinical trials, have helped dozens of patients with otherwise untreatable blood cancers.

read article

Does It Seem As If You Know More Men With Cancer Than Women?

(Washington Post) Mar 13, 2017 - Doctors have puzzled over the stats for years: Cancer strikes 1 in 2 men vs. just 1 in 3 women. Even among babies and children with leukemia, boys are more likely to develop the disease than girls.

read article (free registration required)

FDA Grants Orphan Drug Status to MDS Biologic

(Monthly Prescribing Reference) Mar 9, 2017 - Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to BI 836858 for the treatment of myelodysplastic syndromes (MDS).

read article

Servier, Pfizer Get FDA OK To Start US Testing Of An Off-The-Shelf CAR-T From Cellectis

(Endpoints News) Mar 9, 2017 - Just a month after the FDA signed off on the first US study for an off-the-shelf CAR-T therapy from Cellectis, its partners at Servier and Pfizer now have a green light to begin treating patients in the US with UCART19, an allogeneic therapy for acute lymphoblastic leukemia.

read article

Cancer Pill Gleevec Keeps Patients Alive and Well for a Decade

(NBCNews.com) Mar 9, 2017 - Everyone hopes and wishes for that last-minute cancer breakthrough that will save doomed patients. It almost never actually happens. With Gleevec, it did.

read article

New Drug Combination Targets Aggressive Blood Cancer

(Van Andel Institute) Mar 7, 2017 - Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial.

read press release

A New Way To Reset Gene Expression In Cancer Cells Shows Promise For Leukemia Treatment

(The Rockefeller University) Mar 6, 2017 - New findings from Rockefeller University researchers could guide the development of potent combination therapies that deliver more effective and durable treatment of leukemia.

read article

Swift Childhood Cancer Deaths More Common Than Thought: Study

(Yahoo! News/Agence France-Presse) Mar 6, 2017 - Childhood cancer often strikes its youngest victims the hardest, and the death rate for infants may be up to four times higher than previously thought, US researchers said Monday.

read article

TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL)

(TG Therapeutics) Mar 6, 2017 - Study met its primary endpoint, with TG-1101 (ublituximab) plus ibrutinib increasing Overall Response Rate (ORR) by > 70% over ibrutinib alone; the combination was well tolerated with a safety profile consistent with the Phase 2 study of ublituximab plus ibrutinib recently published in the British Journal of Hematology; targeting full data presentation at a medical meeting in 1H17 and meeting with FDA in 2H17 to discuss the results and filing for accelerated approval.

read corporate press release

TG Therapeutics' Leukemia Drug Clears Key Study, Shares Pop

(Reuters) Mar 6, 2017 - TG Therapeutics Inc said a combination of its experimental cancer drug, ublituximab, and approved treatment Imbruvica was found to be more effective in high-risk leukemia patients, compared with Imbruvica as a standalone therapy.

read article

FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine

(Yahoo! Finance) Mar 6, 2017 - Seattle Genetics, Inc., a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold announced on December 27, 2016 on phase 1 trials of vadastuximab talirine (SGN-CD33A; 33A) in acute myeloid leukemia (AML).

read article

Seattle Genetics to Resume Leukemia Drug Trials After FDA Lifts Hold

(Xconomy Seattle) Mar 6, 2017 - An experimental leukemia drug from Seattle Genetics can resume clinical testing, work that had ground to a halt three months ago following the deaths of four patients.

read article
Next Page